Literature DB >> 17909979

Sensitivity of FCV to recombinant feline interferon (rFeIFN).

Kyoko Ohe1, Toshikazu Takahashi, Daisuke Hara, Motonobu Hara.   

Abstract

Feline calicivirus cause feline respiratory diseases, and inactivated and attenuated vaccines are available for its prevention. Moreover, the presence of vaccine breakdown strains (VBS) is problematic. In Japan, feline recombinant interferon (rFeIFN) has been used for its treatment. However the method of compare with each strains has not established. To examine the relationship between the breakdown vaccine strain and rFeIFN sensitivity, the sensitivity of 47 field isolates to rFeIFN was determined. The Log PDD(50) values were normally distributed within the range 1.1-3.7, with a mean value of 2.3 +/- 0.64. Since 68.3% of the PDD values fell in the range of the mean +/- standard deviation, the values in the range 1.7-2.9, the lower values, and the higher values were defined as representing moderate, low, and high sensitivity, respectively. Among the 15 vaccine breakdown strains, strain Fukuoka9 showed a low sensitivity, but strains ML89, T58, and N74 were highly sensitive, showing no association with vaccine breakdown. The amino acid sequence changes specific to the low rFeIFN-sensitive Fukuoka-9 strain were found, suggesting that these sites are involved in rFeIFN sensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909979     DOI: 10.1007/s11259-007-9019-5

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.816


  11 in total

1.  [Immunizing property of vaccinia virus inactivated by ultraviolets rays].

Authors:  Y NAGANO; Y KOJIMA
Journal:  C R Seances Soc Biol Fil       Date:  1954-10

2.  Studies on vaccinia virus plaque formation and its inhibition by interferon. III. A simplified plaque inhibition assay of interferon.

Authors:  J LINDENMANN; G E GIFFORD
Journal:  Virology       Date:  1963-03       Impact factor: 3.616

3.  Biological studies of interferon. I. Suppression of cellular infection with eastern equine encephalomyelitis virus.

Authors:  R R WAGNER
Journal:  Virology       Date:  1961-03       Impact factor: 3.616

4.  Genogrouping of vaccine breakdown strains (VBS) of feline calicivirus in Japan.

Authors:  K Ohe; S Sakai; T Takahasi; F Sunaga; M Murakami; A Kiuchi; M Fukuyama; K Furuhata; M Hara; Y Ishikawa; A Taneno
Journal:  Vet Res Commun       Date:  2007-05       Impact factor: 2.459

5.  Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2',5'-oligoadenylate synthetase activity in the cat.

Authors:  Y Ueda; T Sakurai; K Kasama; Y Satoh; K Atsumi; S Hanawa; T Uchino; A Yanai
Journal:  J Vet Med Sci       Date:  1993-02       Impact factor: 1.267

6.  Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957.

Authors:  A Isaacs; J Lindenmann
Journal:  J Interferon Res       Date:  1987-10

7.  Recent epidemiological status of feline upper respiratory infections in Japan.

Authors:  M Mochizuki; K Kawakami; M Hashimoto; T Ishida
Journal:  J Vet Med Sci       Date:  2000-07       Impact factor: 1.267

8.  Phylogenetic analysis of field isolates of feline calcivirus (FCV) in Japan by sequencing part of its capsid gene.

Authors:  Y Sato; K Ohe; M Murakami; M Fukuyama; K Furuhata; S Kishikawa; Y Suzuki; A Kiuchi; M Hara; Y Ishikawa; A Taneno
Journal:  Vet Res Commun       Date:  2002-04       Impact factor: 2.459

9.  Hepatitis C virus serotype II responds more favorably to interferon-alpha therapy.

Authors:  E Orito; M Mizokami; N Mizoguchi; K Ohba; M Tohnai; H Yamanaka; T Oguri; N Hirashima; T Koide; H Kano
Journal:  J Hepatol       Date:  1994-07       Impact factor: 25.083

10.  Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro.

Authors:  M Mochizuki; H Nakatani; M Yoshida
Journal:  Vet Microbiol       Date:  1994-03       Impact factor: 3.293

View more
  9 in total

1.  Critical role of RIG-I and MDA5 in early and late stages of Tulane virus infection.

Authors:  Preeti Chhabra; Priya Ranjan; Theresa Cromeans; Suryaprakash Sambhara; Jan Vinjé
Journal:  J Gen Virol       Date:  2017-05-22       Impact factor: 3.891

Review 2.  Calicivirus Infection in Cats.

Authors:  Regina Hofmann-Lehmann; Margaret J Hosie; Katrin Hartmann; Herman Egberink; Uwe Truyen; Séverine Tasker; Sándor Belák; Corine Boucraut-Baralon; Tadeusz Frymus; Albert Lloret; Fulvio Marsilio; Maria Grazia Pennisi; Diane D Addie; Hans Lutz; Etienne Thiry; Alan D Radford; Karin Möstl
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

3.  Antiviral effect of mefloquine on feline calicivirus in vitro.

Authors:  Phillip McDonagh; Paul A Sheehy; Anne Fawcett; Jacqueline M Norris
Journal:  Vet Microbiol       Date:  2015-02-16       Impact factor: 3.293

4.  The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation.

Authors:  Céline Robert-Tissot; Vera L Rüegger; Valentino Cattori; Marina L Meli; Barbara Riond; Maria Alice Gomes-Keller; Andrea Vögtlin; Burghardt Wittig; Christiane Juhls; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

5.  Molecular characterization and biological activity of bovine interferon-omega3.

Authors:  Dong An; Yongli Guo; Jun Bao; Xiuxin Luo; Ying Liu; Bo Ma; Mingchun Gao; Junwei Wang
Journal:  Res Vet Sci       Date:  2017-02-10       Impact factor: 2.534

Review 6.  Interferon-omega: Current status in clinical applications.

Authors:  Shi-Fang Li; Fu-Rong Zhao; Jun-Jun Shao; Yin-Li Xie; Hui-Yun Chang; Yong-Guang Zhang
Journal:  Int Immunopharmacol       Date:  2017-10-12       Impact factor: 4.932

7.  Use of recombinant interferon omega in feline retrovirosis: from theory to practice.

Authors:  Ana Doménech; Guadalupe Miró; Victorio M Collado; Natalia Ballesteros; Leticia Sanjosé; Elena Escolar; Sonsoles Martin; Esperanza Gomez-Lucia
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

8.  Induction of a systemic antiviral state in vivo in the domestic cat with a class A CpG oligonucleotide.

Authors:  Céline Robert-Tissot; Marina L Meli; Barbara Riond; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Immunol Immunopathol       Date:  2012-08-04       Impact factor: 2.046

9.  Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families.

Authors:  Céline Robert-Tissot; Vera L Rüegger; Valentino Cattori; Marina L Meli; Barbara Riond; Peter F Moore; Monika Engels; Marco Franchini; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Res       Date:  2012-08-20       Impact factor: 3.683

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.